No Data
Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36
Wedbush analyst Robert Driscoll maintains $Cullinan Therapeutics(CGEM.US)$ with a buy rating, and maintains the target price at $36.According to TipRanks data, the analyst has a success rate of 43.1%
Express News | Cullinan Therapeutics Receives Approval to Initiate Its Global Phase 1 Clinical Trial of Cln-978
TD Cowen Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating
TD Cowen analyst Marc Frahm maintains $Cullinan Therapeutics(CGEM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 55.5% and a total average return of 18.5% over
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $40
Stifel analyst Bradley Canino maintains $Cullinan Therapeutics(CGEM.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 47.1%
Express News | Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for Cln-978 to Treat Systemic Lupus Erythematosus
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28
H.C. Wainwright analyst Edward White maintains $Cullinan Therapeutics(CGEM.US)$ with a buy rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 3